Securities and Exchange Board of India (SEBI) has directed prohibition on securities market's access and restraining from buying, selling or otherwise dealing in the securities, either directly or indirectly or in any other manner whatsoever, for a period of one year, to Morepen Laboratories. In this regard, the Company is seeking advice for pursuing suitable remedies including filing of appeal before the appropriate forum.
Morepen Laboratories is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.
